Ginkgo Bioworks Holdings Inc.(DNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DNA Ginkgo Bioworks Holdings Inc.

Pre-Mkt 01-13 06:11:34 EST

9.56

+0.32

+3.46%

盘前9.62

+0.06+0.63%

05:57 EST

High9.69	Low9.06	Vol782.73K
Open9.33	D1 Closing9.24	Amplitude6.82%
Mkt Cap579.24M	Tradable Cap397.09M	Total Shares60.59M
T/O7.37M	T/O Rate1.88%	Tradable Shares41.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DNA","market":"US","secType":"STK","nameCN":"Ginkgo Bioworks Holdings Inc.","latestPrice":9.56,"timestamp":1768251600000,"preClose":9.24,"halted":0,"volume":782733,"hourTrading":{"tag":"盘前","latestPrice":9.62,"preClose":9.56,"latestTime":"05:57 EST","volume":448,"amount":4329.160192,"timestamp":1768301840236},"delay":0,"floatShares":41536899,"shares":60590219,"eps":-6.213238,"marketStatus":"Pre-Mkt","change":0.32,"latestTime":"01-13 06:11:34 EST","open":9.33,"high":9.69,"low":9.06,"amount":7368762.741018,"amplitude":0.068182,"askPrice":9.68,"askSize":189,"bidPrice":9.35,"bidSize":56,"shortable":3,"etf":0,"ttmEps":-6.213238,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768314600000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":9.56,"preHourTrading":{"tag":"盘前","latestPrice":9.62,"preClose":9.56,"latestTime":"05:57 EST","volume":448,"amount":4329.160192,"timestamp":1768301840236},"postHourTrading":{"tag":"盘后","latestPrice":9.68,"preClose":9.56,"latestTime":"19:51 EST","volume":24239,"amount":231356.1432,"timestamp":1768265518902},"volumeRatio":0.7961555456225288,"impliedVol":0.6715,"impliedVolPercentile":0.02},"requestUrl":"/m/hq/s/DNA/wiki","defaultTab":"wiki","newsList":[{"id":"2602581249","title":"What Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602581249","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602581249?lang=en_us&edition=fundamental","pubTime":"2026-01-10 15:16","pubTimestamp":1768029368,"startTime":"0","endTime":"0","summary":"In 2025, Twist Bioscience’s CEO and Chair Emily M. Leproust received total compensation of US$13,781,570, while recent insider activity showed only stock sales and no purchases alongside adjustments in institutional holdings. \nAt the same time, multiple brokerage firms reiterated positive views on Twist Bioscience’s semiconductor-based DNA synthesis platform, collectively maintaining an “Outperform” stance backed by confidence in its synthetic biology technology. \nBuilding on this renewed...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/what-does-ceo-pay-and-insider-selling-reveal-about-twist-bio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/what-does-ceo-pay-and-insider-selling-reveal-about-twist-bio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DNA","TWST","BK4109","BK4585","BK4588","BK4121"],"gpt_icon":0},{"id":"2601355386","title":"U.S. RESEARCH ROUNDUP-Alcoa, BlackRock, Evercore","url":"https://stock-news.laohu8.com/highlight/detail?id=2601355386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601355386?lang=en_us&edition=fundamental","pubTime":"2026-01-08 15:12","pubTimestamp":1767856359,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alcoa, BlackRock, EvercoreJan 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alcoa, BlackRock...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL4N3Y90FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130103400.USD","COMP","IVZ","PAYC","GLUE","SG9999002232.USD","GMED","CBRE","BK4533","PJT","OS","AA","LU2272731600.USD","ACI","BX","LU1804176565.USD","APD","ARES","CACC","INTU","HALO","BLK","DNA","F","JLL","RIVN","FHI","HLNE","CTSH","GM","AMG","FCX","AZTA","KKR","BWA","LU0971096721.USD","EPAM","APO","MSM","IE","FIGR","BK4139","EXE","PCTY","HLI","SG9999002224.SGD","EVR","GDYN","BK4534","CG"],"gpt_icon":1},{"id":"2601304123","title":"We Think Bumitama Agri (SGX:P8Z) Might Have The DNA Of A Multi-Bagger","url":"https://stock-news.laohu8.com/highlight/detail?id=2601304123","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601304123?lang=en_us&edition=fundamental","pubTime":"2026-01-08 07:47","pubTimestamp":1767829648,"startTime":"0","endTime":"0","summary":"To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/5121000-choice1-main-header/1585186829794","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5121000-choice1-main-header/1585186829794"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/sg/food-beverage-tobacco/sgx-p8z/bumitama-agri-shares/news/we-think-bumitama-agri-sgxp8z-might-have-the-dna-of-a-multi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/sg/food-beverage-tobacco/sgx-p8z/bumitama-agri-shares/news/we-think-bumitama-agri-sgxp8z-might-have-the-dna-of-a-multi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","BK6095","BK4109","DNA","BK6509","EBIT","P8Z.SI","SG9999006266.SGD","BK4139"],"gpt_icon":0},{"id":"2601422818","title":"YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2601422818","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601422818?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:00","pubTimestamp":1767708000,"startTime":"0","endTime":"0","summary":"Taipei, Taiwan, Jan.  06, 2026  (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213679/0/en/YD-Bio-Enters-into-MOU-to-Merge-with-EG-BioMed-Advancing-DNA-Methylation-Driven-AI-Platforms-for-Cancer-Diagnostics-and-Drug-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4585","BK4139","AI","BK4121","DNA","LU0211331839.USD","BK4588","BK4109","BK4551","EG","BK4587","IE0002270589.USD","IE00B19Z3581.USD","BK4528","LU0077335932.USD","BK4543","BK4019","BK4023"],"gpt_icon":0},{"id":"1122016155","title":"National Forest and Grass Germplasm Resource Xiong'an Facility Set for Year-End Completion, First Specimens Hold Major Significance","url":"https://stock-news.laohu8.com/highlight/detail?id=1122016155","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122016155?lang=en_us&edition=fundamental","pubTime":"2026-01-04 16:14","pubTimestamp":1767514465,"startTime":"0","endTime":"0","summary":"The National Forest and Grass Germplasm Resource Facility Preservation Bank (Xiong'an) is projected to be completed by the end of this year and will become operational in 2028. The facility is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNA","BK4121","BK4109","BK4139"],"gpt_icon":0},{"id":"2593446879","title":"Ginkgo Bioworks Names Jennifer Wipf to Oversee Operations as Reshma Shetty Shifts Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446879","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593446879?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:26","pubTimestamp":1766528804,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks Holdings Inc. announced that Dr. Reshma Shetty will transition her Chief Operating Officer duties to Jennifer Wipf and CEO Dr. Jason Kelly effective January 1, 2026. Dr. Shetty will continue as President and a Board member, focusing on expanding the company’s autonomous lab and cell engineering services. Jennifer Wipf, previously Chief Commercial Officer and General Manager, will take on responsibilities for operations, reporting to Dr. Kelly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Decemb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL8CqkS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4109","DNA","BK4121"],"gpt_icon":0},{"id":"2593437717","title":"Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2593437717","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593437717?lang=en_us&edition=fundamental","pubTime":"2025-12-23 03:53","pubTimestamp":1766433229,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks  is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.Ginkgo plans to support the program with its cell and enzyme engineering capabilities.Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.Ginkgo shares rose 8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DNA","DNA.AU","HBCP","BK4139","BK4211","BK4109","BK7078","BK4121","BK4195"],"gpt_icon":0},{"id":"1167673593","title":"A Billion-Dollar Fund's \"DNA Reconstruction\" Experiment: Central Huijin's Entry, Management Reshuffle, and Sustained Performance Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1167673593","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167673593?lang=en_us&edition=fundamental","pubTime":"2025-12-22 18:46","pubTimestamp":1766400360,"startTime":"0","endTime":"0","summary":"As the year-end approaches, the race for performance among public funds has entered its final sprint. By December 11, 2025, four funds have quietly surpassed the 140% return threshold, vying for top...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4139","DNA","BK4109"],"gpt_icon":0},{"id":"2592816702","title":"Article 6.4: a six-month deadline extension keeps PACM’s doors open to roughly 1bn CDM credits","url":"https://stock-news.laohu8.com/highlight/detail?id=2592816702","media":"Fastmarkets","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592816702?lang=en_us&edition=fundamental","pubTime":"2025-12-19 13:00","pubTimestamp":1766120400,"startTime":"0","endTime":"0","summary":"The Paris Agreement parties have extended the host party approval deadline for CDM carbon credits transitioning to the PACM from December 2025 to June 2026, with additional documentation deadlines pushed to December 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fastmarkets_highlight","url":"https://www.fastmarkets.com/insights/article-6-4-a-six-month-deadline-extension-keeps-pacms-doors-open-to-roughly-1bn-cdm-credits/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fastmarkets.com/insights/article-6-4-a-six-month-deadline-extension-keeps-pacms-doors-open-to-roughly-1bn-cdm-credits/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"fastmarkets_highlight","symbols":["BK4110","BK4139","ARR","BK4121","BK4109","DNA"],"gpt_icon":0},{"id":"2592168990","title":"Ginkgo Bioworks and Agricen Collaborate to Optimize Soil Amendment Fermentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592168990","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592168990?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:02","pubTimestamp":1765976526,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks Holdings Inc. has announced the successful completion of its initial collaboration with Agricen, a leader in biological and soil amendment solutions for plant nutrition and health. The partnership focused on developing and optimizing a low-cost, efficient fermentation process for complex bacterial strains used in one of Agricen's soil amendment products. By leveraging Ginkgo's expertise in process development, Agricen was able to accelerate the production of these microbes, allowing for greater operational efficiency and more focus on advancing new biological crop nutrition solutions. The collaboration underscores Ginkgo's commitment to providing next-generation agricultural solutions and supporting partners at various stages of bioprocess development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLb8C2jy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNA","BK4121","BK4109","BK4139"],"gpt_icon":0},{"id":"2592990677","title":"Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990677","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990677?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA9LXCKB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4109","BK4139","DNA"],"gpt_icon":0},{"id":"2590347079","title":"Ginkgo Bioworks Partners With Deep Origin-Led Team on ARPA-H to Develop Drug Safety Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2590347079","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590347079?lang=en_us&edition=fundamental","pubTime":"2025-12-09 23:26","pubTimestamp":1765293967,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks  said Tuesday it is partnering with Deep Origin on a 4.5-year project funded by advanced Research Projects Agency for Health, or ARPA-H, to develop a computational platform for predicting drug safety.Under the collaboration, Ginkgo Bioworks said it will use its Datapoints platform to produce high-throughput data sets for training AI models, including small-molecule and genetic perturbation data across multiple cell and tissue types.Readouts will include cell type-specific toxicity endpoints, transcriptomics and cell-painting, the company said.Price: 9.52, Change: +0.12, Percent Change: +1.22","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4109","BK4120","BK7078","TISI","DNA.AU","DNA","BK4121"],"gpt_icon":0},{"id":"2589909448","title":"BRIEF-Ginkgo Bioworks Holdings Inc - Selected By Pnnl To Deliver A Modular, High‑Throughput Phenotyping Platform For Doe's M2pc","url":"https://stock-news.laohu8.com/highlight/detail?id=2589909448","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589909448?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:37","pubTimestamp":1764941879,"startTime":"0","endTime":"0","summary":"BRIEF-Ginkgo Bioworks Holdings Inc - Selected By Pnnl To Deliver A Modular, HighThroughput Phenotyping Platform For Doe's M2pcDec 5 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N:GINKGO BIOWORKS HOLDI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4139","DNA","BK4109"],"gpt_icon":0},{"id":"2589910890","title":"Ginkgo Bioworks Holdings Inc - Awarded by Environmental Molecular Sciences Laboratory a Four-Year, up to $47M Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2589910890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589910890?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:35","pubTimestamp":1764941743,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BK4109","BK4139","DNA"],"gpt_icon":0},{"id":"2589890950","title":"Ginkgo Bioworks Holdings Inc - Selected by Pnnl to Deliver a Modular, High‑Throughput Phenotyping Platform for Doe's M2PC","url":"https://stock-news.laohu8.com/highlight/detail?id=2589890950","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589890950?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:35","pubTimestamp":1764941743,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNA","BK4109","BK4121","BK4139"],"gpt_icon":0},{"id":"2589673890","title":"Ginkgo Bioworks Wins Up to $47 Million Contract to Build Automated Phenotyping Platform for PNNL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589673890","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589673890?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:34","pubTimestamp":1764941673,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks Holdings Inc. announced it has been awarded a four-year contract worth up to $47 million by the Environmental Molecular Sciences Laboratory at Pacific Northwest National Laboratory. Under the agreement, Ginkgo will co-design, build, and integrate a High-Throughput Automated Phenotyping Platform to support the Department of Energy's Microbial Molecular Phenotyping Capability. The platform aims to enable large-scale, reproducible microbial and microbiome data generation and will utilize Ginkgo Automation's Catalyst scheduling software and modular Reconfigurable Automation Carts. The initiative is intended to enhance phenotyping throughput, support AI/ML applications, and provide a scalable foundation for future research instrumentation and workflows.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL66ht8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4109","BK4139","DNA"],"gpt_icon":0},{"id":"2589783924","title":"Is Twist’s New Endotoxin‑Controlled Plasmid DNA Offering Altering The Investment Case For TWST?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589783924","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589783924?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:18","pubTimestamp":1764865137,"startTime":"0","endTime":"0","summary":"Twist Bioscience recently launched research-grade Plasmid DNA Preps to support pharmaceutical and biotech customers’ preclinical studies, offering animal origin-free and low or endotoxin-free, transfection-grade options with precise target yields from 4ug to 10ug.\nThis move underscores Twist’s effort to become a more integrated partner in nucleic acid therapeutics discovery by reducing variability and quality risk for customers’ sensitive cell-based workflows.\nNext, we’ll examine how Twist’s...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/is-twists-new-endotoxincontrolled-plasmid-dna-offering-alter","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/is-twists-new-endotoxincontrolled-plasmid-dna-offering-alter","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4109","BK4139","BK4121","TWST","DNA","BK4588"],"gpt_icon":0},{"id":"2588887713","title":"Twist Bioscience Introduces New Plasmid DNA Preparation Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887713","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887713?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:07","pubTimestamp":1764857225,"startTime":"0","endTime":"0","summary":"Twist Bioscience  said Thursday it launched animal-origin-free and transfection-grade plasmid DNA preparation products for nucleic acid therapeutics research.The new products are designed to meet specific quality needs for preclinical studies, including low or endotoxin-free requirements for work involving sensitive cells, according to Twist.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","DNA","BK4109","BK4139","BK4588","BK4585","TWST"],"gpt_icon":0},{"id":"2588075046","title":"Ginkgo Bioworks Joins STRM.BIO-Led Consortium to Advance In Vivo CAR-T Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2588075046","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588075046?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:01","pubTimestamp":1764766884,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks Holdings Inc. has entered into a collaboration with STRM.BIO, the University of British Columbia , and Advanced Bioprocess Services  to advance the development of in vivo CAR-T therapeutics. This partnership is supported by an ARPA-H contract awarded to STRM.BIO under the EMBODY program, with up to $8.4 million in funding for the first phase. Ginkgo Bioworks will contribute its expertise in RNA construct design and immune cell engineering to help develop STRM.BIO's megakaryocyte-derived extracellular vesicle delivery platform, aiming to create innovative, non-viral approaches to cell and gene therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to gene","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL103sHN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4121","DNA","BK4109"],"gpt_icon":0},{"id":"2588056701","title":"Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056701","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056701?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:55","pubTimestamp":1764683700,"startTime":"0","endTime":"0","summary":"The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"investorplace_stock_picks","url":"https://investorplace.com/hypergrowthinvesting/2025/12/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://investorplace.com/hypergrowthinvesting/2025/12/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["IONQ","SNVD.UK","NVIW.SI","TWST","MU","CEG","DNA","PPTA","ROIC","NVD2.UK","ABSI","NVDU","WOLF","SGXZ31699556.SGD","BWXT","SMR","NVDD","RXRX","2NVD.UK","MP","SLI","NNE","SYM","HON","TER","QBTS","NVDS","LU1429558221.USD","LU0274383776.USD","NVDL","NVD","TMQ","LEU","LU0265550359.USD","NVDY","RGTI","NVDX","SKYT","TMO","NVDS.UK","SDGR","3NVD.UK","OKLO","LU2023251221.USD","NVD3.UK","ROK","NVDA","AI","INTC","LAC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ginkgobioworks.com","stockEarnings":[{"period":"1week","weight":0.0778},{"period":"1month","weight":0.0236},{"period":"3month","weight":-0.3215},{"period":"6month","weight":-0.0042},{"period":"1year","weight":-0.0225},{"period":"ytd","weight":0.1504}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.020069},{"month":2,"riseRate":0.25,"avgChangeRate":-0.155171},{"month":3,"riseRate":0,"avgChangeRate":-0.186194},{"month":4,"riseRate":0.25,"avgChangeRate":-0.075483},{"month":5,"riseRate":0.4,"avgChangeRate":-0.028577},{"month":6,"riseRate":0.6,"avgChangeRate":0.042062},{"month":7,"riseRate":0.8,"avgChangeRate":0.169362},{"month":8,"riseRate":0.2,"avgChangeRate":-0.142535},{"month":9,"riseRate":0.8,"avgChangeRate":0.092966},{"month":10,"riseRate":0.2,"avgChangeRate":-0.069954},{"month":11,"riseRate":0.2,"avgChangeRate":-0.122886},{"month":12,"riseRate":0.4,"avgChangeRate":-0.023276}],"exchange":"NYSE","name":"Ginkgo Bioworks Holdings Inc.","nameEN":"Ginkgo Bioworks Holdings Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ginkgo Bioworks Holdings Inc.(DNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ginkgo Bioworks Holdings Inc.(DNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ginkgo Bioworks Holdings Inc.,DNA,Ginkgo Bioworks Holdings Inc.股票,Ginkgo Bioworks Holdings Inc.股票老虎,Ginkgo Bioworks Holdings Inc.股票老虎国际,Ginkgo Bioworks Holdings Inc.行情,Ginkgo Bioworks Holdings Inc.股票行情,Ginkgo Bioworks Holdings Inc.股价,Ginkgo Bioworks Holdings Inc.股市,Ginkgo Bioworks Holdings Inc.股票价格,Ginkgo Bioworks Holdings Inc.股票交易,Ginkgo Bioworks Holdings Inc.股票购买,Ginkgo Bioworks Holdings Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ginkgo Bioworks Holdings Inc.(DNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ginkgo Bioworks Holdings Inc.(DNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction